CL2021002464A1 - Composición farmacéutica, que comprende la variante de hialuronidasa humana ph20 y fármaco, para inyección subcutánea. - Google Patents

Composición farmacéutica, que comprende la variante de hialuronidasa humana ph20 y fármaco, para inyección subcutánea.

Info

Publication number
CL2021002464A1
CL2021002464A1 CL2021002464A CL2021002464A CL2021002464A1 CL 2021002464 A1 CL2021002464 A1 CL 2021002464A1 CL 2021002464 A CL2021002464 A CL 2021002464A CL 2021002464 A CL2021002464 A CL 2021002464A CL 2021002464 A1 CL2021002464 A1 CL 2021002464A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
variant
human
drug
present disclosure
Prior art date
Application number
CL2021002464A
Other languages
English (en)
Inventor
Hye-Shin Chung
Seung Joo Lee
Kyuwan Kim
Minsoo Byun
Ki Seok Nam
Soon Jae Park
Original Assignee
Alteogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72611090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2021002464(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alteogen Inc filed Critical Alteogen Inc
Publication of CL2021002464A1 publication Critical patent/CL2021002464A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente divulgación se refiere a una composición farmacéutica que incluye (a) un fármaco y (b) una variante de PH20 humana. La variante de PH20 humana incluida en la composición farmacéutica de acuerdo con la presente divulgación incluye una sustitución o sustituciones de residuos de amino ácidos en una o más regiones seleccionadas entre una región de hélice alfa 8 (S347 a C381) y una región enlazadora (A333 a R346) entre la hélice alfa 7 y la hélice alfa 8 en PH20 humana de tipo silvestre que tiene la secuencia de amino ácidos de SEQ ID NO: 1, en donde residuo(s) de amino ácidos ubicado(s) en el terminal N o el terminal C es(son) escindidos selectivamente. Adicionalmente, la composición farmacéutica de acuerdo con la presente divulgación puede incluir además un aditivo farmacéuticamente aceptable, particularmente un estabilizador. La composición farmacéutica de acuerdo con la presente divulgación puede maximizar el efecto terapéutico de un fármaco usado en combinación con la misma, debido al efecto de variantes de PH20 humana.
CL2021002464A 2019-03-25 2021-09-22 Composición farmacéutica, que comprende la variante de hialuronidasa humana ph20 y fármaco, para inyección subcutánea. CL2021002464A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20190033880 2019-03-25

Publications (1)

Publication Number Publication Date
CL2021002464A1 true CL2021002464A1 (es) 2022-07-22

Family

ID=72611090

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002464A CL2021002464A1 (es) 2019-03-25 2021-09-22 Composición farmacéutica, que comprende la variante de hialuronidasa humana ph20 y fármaco, para inyección subcutánea.

Country Status (25)

Country Link
US (2) US12570766B2 (es)
EP (2) EP4461811A3 (es)
JP (4) JP7295150B2 (es)
KR (3) KR102507853B1 (es)
CN (7) CN117100867A (es)
AU (2) AU2020248612B9 (es)
BR (1) BR112021019076A2 (es)
CA (1) CA3131052A1 (es)
CL (1) CL2021002464A1 (es)
CO (1) CO2021012380A2 (es)
CR (1) CR20210489A (es)
DO (1) DOP2021000197A (es)
EA (1) EA202192588A1 (es)
EC (1) ECSP21070640A (es)
IL (1) IL286539A (es)
JO (1) JOP20210262A1 (es)
MX (2) MX2021011278A (es)
MY (1) MY204342A (es)
NI (1) NI202100085A (es)
PE (1) PE20220283A1 (es)
PH (1) PH12021552351A1 (es)
SA (1) SA521430398B1 (es)
SG (1) SG11202110512WA (es)
WO (1) WO2020197230A1 (es)
ZA (2) ZA202108027B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
EP3130347B1 (en) 2011-12-30 2019-09-18 Halozyme, Inc. Ph20 polypeptide variants, formulations and uses thereof
KR102460040B1 (ko) 2016-04-27 2022-11-01 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
US11103552B2 (en) 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations
EP3636752A4 (en) 2018-07-25 2021-04-28 Alteogen, Inc. NEW HYALURONIC ACID HYDROLYZING ENZYMUTANTS AND THE PHARMACEUTICAL COMPOSITION CONTAINING THIS
KR102885113B1 (ko) 2018-10-18 2025-11-13 머크 샤프 앤드 돔 엘엘씨 항-rsv 항체의 제제 및 그의 사용 방법
CN120842406A (zh) 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
MY204342A (en) 2019-03-25 2024-08-24 Alteogen Inc Pharmaceutical composition, comprising human hyaluronidase ph20 variant and drug, for subcutaneous injection
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
EP3992285A4 (en) * 2020-01-23 2023-01-25 Alteogen, Inc. NOVEL HYALURONIC HYDROLYZING ENZYME VARIANT WITH IMPROVED STABILITY AND PHARMACEUTICAL COMPOSITION CONTAINING IT
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
JP2023534295A (ja) 2020-07-17 2023-08-08 ジェロン・コーポレーション 皮下テロメラーゼ阻害剤組成物及びそれらを使用するための方法
JP7622088B2 (ja) 2020-08-07 2025-01-27 アルテオジェン・インコーポレイテッド 組換えヒアルロニダーゼの生産方法
IL301533A (en) * 2020-09-24 2023-05-01 Merck Sharp ַ& Dohme Llc Stable compositions of programmed death receptor 1 (PD-1) antibodies and hyaluronidase variants and parts thereof and methods of using them
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Pharmaceutical compositions of a her2/neu antibody and use of the same
JP2024501029A (ja) 2020-12-28 2024-01-10 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
SMT202500208T1 (it) 2020-12-28 2025-07-22 Bristol Myers Squibb Co Composizioni anticorpali e metodi per il loro uso
CN114681592A (zh) * 2020-12-31 2022-07-01 天境生物科技(杭州)有限公司 包含可溶性gp130二聚体的制剂和使用方法
US20240156907A1 (en) * 2021-03-16 2024-05-16 Kashiv Biosciences, Llc Novel formulation of fusion protein
TW202305009A (zh) * 2021-04-08 2023-02-01 美商默沙東有限責任公司 以皮下投予抗pd1抗體治療癌症之方法
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
CN115671267A (zh) * 2021-07-23 2023-02-03 上海宝济药业有限公司 一种皮下抗生素药物组合物
WO2023012515A2 (en) 2021-08-02 2023-02-09 argenx BV Subcutaneous unit dosage forms
CA3232451A1 (en) 2021-09-14 2023-03-23 Takeda Pharmaceutical Company Limited Facilitated delivery of concentrated antibody formulations using hyaluronidase
EP4424301A4 (en) * 2021-10-29 2025-11-19 Alteogen Inc Pharmaceutical composition comprising a human PH20 hyaluronidase and a medicinal product
US20250099612A1 (en) 2022-03-01 2025-03-27 Exuma Biotech Corp. Viral particles with membrane-bound hyaluronidase
IL314840A (en) * 2022-03-07 2024-10-01 Mabxience Res S L Stable Antibody Formulations
JP2025513510A (ja) * 2022-04-20 2025-04-24 アルトス バイオロジックス インク． オクレリズマブを含む薬学的組成物とその用途
CN119095620A (zh) * 2022-04-22 2024-12-06 台康生技股份有限公司 用于皮下投予的包含抗-her2抗体的药学组合物
EP4531916A1 (en) 2022-06-02 2025-04-09 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2023249408A1 (ko) * 2022-06-22 2023-12-28 (주)알테오젠 N-말단 및/또는 c-말단이 절단된 가용성 ph20 폴리펩티드 및 이의 용도
WO2024005502A1 (ko) * 2022-06-29 2024-01-04 주식회사 오디스젠 중성 ph에서 활성을 나타내는 히알루로니다제 hyal1 변이체
KR20240038901A (ko) * 2022-09-16 2024-03-26 (주)피앤피바이오팜 신규한 히알루로니다제 ph-20 변이체 및 그 용도
WO2024117476A1 (ko) * 2022-11-28 2024-06-06 주식회사 대웅제약 생체이용률이 개선된 니클로사마이드 함유 조성물
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
IL321611A (en) 2022-12-22 2025-08-01 Halozyme Inc High-dose hyaluronidase enzyme formulations
KR102554775B1 (ko) * 2023-02-07 2023-07-12 한국코러스 주식회사 히알루로니다제의 안정화제 및 이를 포함하는 히알루로니다제 제형
CN120936711A (zh) * 2023-03-23 2025-11-11 阿特根公司 新型透明质酸酶变体及包括其的药物组合物
EP4727534A1 (en) * 2023-06-19 2026-04-22 Stanislaw R. Burzynski Compositions comprising antineoplastons and methods of treating breast cancer
IL325726A (en) * 2023-07-11 2026-03-01 Genentech Inc Compositions and methods for treating multiple sclerosis
WO2025071366A1 (ko) * 2023-09-27 2025-04-03 삼성바이오에피스 주식회사 항-il-23 항체의 자가-완충 액상 제형
KR20250086876A (ko) * 2023-12-06 2025-06-16 (주)한국비엠아이 히알루로니다제 폴리펩티드와 약물을 포함하는 피하투여용 조성물
KR102896967B1 (ko) * 2023-12-21 2025-12-09 주식회사 오디스젠 개선된 특성을 갖는 히알루로니다제 Hyal2 변이체
WO2025136032A1 (ko) * 2023-12-21 2025-06-26 주식회사 오디스젠 개선된 특성을 갖는 히알루로니다제 hyal2 변이체
WO2025168089A1 (zh) * 2024-02-08 2025-08-14 上海宝济药业股份有限公司 用于皮下给药的药物组合及其应用
WO2025188901A1 (en) * 2024-03-05 2025-09-12 Halozyme, Inc. Combination therapy with antibody-drug conjugates and hyaluronidases
WO2025231015A1 (en) * 2024-04-30 2025-11-06 Context Therapeutics Inc. Compositions comprising bispecific antibodies that bind to claudin 6 and cd3, and uses thereof
WO2025249934A1 (ko) * 2024-05-29 2025-12-04 (주)알테오젠 성장 호르몬 수용체 길항제 및 지속성 담체를 포함하는 피하 주사용 약학 조성물
WO2025264960A1 (en) 2024-06-21 2025-12-26 Apogee Therapeutics, Inc. Antibodies that bind il-13 and antibodies that bind ox40l
WO2025264972A1 (en) 2024-06-21 2025-12-26 Apogee Therapeutics, Inc. Antibodies that bind il-4r alpha and antibodies that bind
WO2026001707A1 (zh) * 2024-06-27 2026-01-02 上海复宏汉霖生物技术股份有限公司 一种新型透明质酸酶变体
WO2026043335A1 (ko) * 2024-08-22 2026-02-26 (주)셀트리온 안정한 약제학적 제제
KR20260044819A (ko) * 2024-09-25 2026-04-02 (주)알테오젠 항체-약물 접합체와 병용하여 사용되는 히알루로니다제를 포함하는 피하 투여 제형의 용도, 및 이를 이용한 질병의 치료 방법

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721348A (en) 1990-12-14 1998-02-24 University Of Connecticut DNA encoding PH-20 proteins
US5958750A (en) 1996-07-03 1999-09-28 Inctye Pharmaceuticals, Inc. Human hyaluronidase
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
ES2532399T3 (es) 2003-03-05 2015-03-26 Halozyme, Inc. Glicoproteína hialuronidasa soluble (sHASEGP), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden
US20090123367A1 (en) 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
CN101384621A (zh) 2005-11-10 2009-03-11 受体生物公司 产生受体和配体同种型的方法
WO2009037566A2 (en) 2007-06-19 2009-03-26 Uvarkina Tamara P Hyaluronidase and method of use thereof
ITMI20072225A1 (it) 2007-11-23 2009-05-24 Luso Farmaco Inst "composizioni farmaceutiche a base di antagonisti della bradichinina ed acido ialuronico e loro uso"
KR20140130512A (ko) 2008-03-06 2014-11-10 할로자임, 아이엔씨 가용성 히알루로니다아제의 대규모 제조
TWI489994B (zh) * 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
KR20100135291A (ko) 2008-04-14 2010-12-24 할로자임, 아이엔씨 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도
CN103205407B (zh) 2008-12-09 2016-03-16 哈洛齐梅公司 延长的可溶性ph20多肽及其用途
ES2573462T3 (es) 2008-12-09 2016-06-08 Halozyme, Inc. Polipéptidos de PH20 soluble extendida y usos de los mismos
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
US20100305500A1 (en) 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
AU2013202020B2 (en) 2009-07-31 2014-11-27 F. Hoffmann-La Roche Ag Subcutaneous anti-HER2 antibody formulation
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
MX2012003282A (es) 2009-09-17 2012-04-30 Baxter Healthcare Sa Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso.
ES2676205T3 (es) 2011-03-31 2018-07-17 Merck Sharp & Dohme Corp. Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados
EP2720712B1 (en) 2011-06-17 2016-03-02 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
EP3130347B1 (en) 2011-12-30 2019-09-18 Halozyme, Inc. Ph20 polypeptide variants, formulations and uses thereof
CN103173474B (zh) 2013-03-27 2014-08-27 广州白云山拜迪生物医药有限公司 一种用于cho细胞表达可溶性重组人透明质酸酶ph20的基因序列
JP6357363B2 (ja) 2013-06-26 2018-07-11 株式会社半導体エネルギー研究所 記憶装置
TW201534726A (zh) * 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
MX2016006275A (es) 2013-11-13 2017-01-05 Tillotts Pharma Ag Sistema multiparticulado para administrar drogas.
WO2015095404A2 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancers using pd-1 axis binding antagonists and taxanes
AU2014364606A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
JP6537076B2 (ja) * 2014-07-31 2019-07-03 国立大学法人神戸大学 分泌シグナルペプチドならびにそれを利用したタンパク質の分泌および細胞表層提示
HRP20190881T1 (hr) 2014-08-28 2019-07-12 Halozyme, Inc. Kombinacijska terapija s hijaluronan-razgrađujućim enzimom i inhibitorom imunološke kontrolne točke
ES2753391T3 (es) 2014-10-14 2020-04-08 Halozyme Inc Composiciones de adenosina desaminasa 2 (ADA2), variantes de la misma y métodos de uso de las mismas
CN104745553B (zh) 2015-03-27 2017-11-28 杭州北斗生物技术有限公司 重组人透明质酸酶及其制备方法和采用聚乙二醇共价修饰的化合物和方法
CA2896038C (en) 2015-07-03 2022-08-09 Glycobiosciences Inc. Polymer matrix compositions comprising a high concentration of bio-fermented sodium hyaluronate and uses thereof
US9995753B2 (en) 2015-09-25 2018-06-12 Merck Sharp & Dohme Corp. Anti-pembrolizumab antibodies
KR101843927B1 (ko) * 2015-10-27 2018-03-30 주식회사 이에이치엘바이오 15-pgdh 억제제를 처리한 세포 또는 그것의 배양물을 포함하는 조성물과 그의 용도
DK3827845T3 (da) 2015-11-03 2022-05-23 Janssen Biotech Inc Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf
AR107483A1 (es) 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
CN105567606B (zh) 2016-03-02 2019-03-19 青岛海洋生物医药研究院股份有限公司 一种球形节杆菌及其产生的透明质酸酶
WO2018052818A1 (en) 2016-09-16 2018-03-22 Henlix, Inc. Anti-pd-1 antibodies
EP3548096B1 (en) 2016-11-30 2024-11-20 Memorial Sloan Kettering Cancer Center Inhibitor-functionalized ultrasmall nanoparticles and methods thereof
US11077189B2 (en) 2017-03-02 2021-08-03 Genentech Inc. Adjuvant treatment of HER2-positive breast cancer
KR102775647B1 (ko) 2017-03-31 2025-03-06 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
SG11201910134SA (en) 2017-05-02 2019-11-28 Merck Sharp & Dohme Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
EP3630179A2 (en) 2017-05-30 2020-04-08 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
MA52789A (fr) 2018-02-13 2021-04-14 Merck Sharp & Dohme Méthodes de traitement du cancer avec des anticorps anti-pd-1
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
EP3636752A4 (en) 2018-07-25 2021-04-28 Alteogen, Inc. NEW HYALURONIC ACID HYDROLYZING ENZYMUTANTS AND THE PHARMACEUTICAL COMPOSITION CONTAINING THIS
TWI852940B (zh) 2018-09-04 2024-08-21 美商泰沙羅公司 治療癌症之方法
WO2020097141A1 (en) 2018-11-07 2020-05-14 Merck Sharp & Dohme Corp. Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
AU2020225631A1 (en) 2019-02-22 2021-09-16 Memorial Sloan Kettering Cancer Center CD33 antibodies and methods of using the same to treat cancer
MY204342A (en) 2019-03-25 2024-08-24 Alteogen Inc Pharmaceutical composition, comprising human hyaluronidase ph20 variant and drug, for subcutaneous injection
ES3063234T3 (en) 2019-12-20 2026-04-15 Formycon Ag Formulations of anti-pd1 antibodies
MX2022008208A (es) 2020-01-03 2022-10-21 Incyte Corp Terapia de combinación que comprende inhibidores de a2a/a2b y proteína de muerte programada 1 /ligando de muerte programada 1 (pd-1/pdl1).
EP3992285A4 (en) 2020-01-23 2023-01-25 Alteogen, Inc. NOVEL HYALURONIC HYDROLYZING ENZYME VARIANT WITH IMPROVED STABILITY AND PHARMACEUTICAL COMPOSITION CONTAINING IT
JP7622088B2 (ja) 2020-08-07 2025-01-27 アルテオジェン・インコーポレイテッド 組換えヒアルロニダーゼの生産方法
IL301533A (en) 2020-09-24 2023-05-01 Merck Sharp ַ& Dohme Llc Stable compositions of programmed death receptor 1 (PD-1) antibodies and hyaluronidase variants and parts thereof and methods of using them
IL302346A (en) 2020-10-28 2023-06-01 Ikena Oncology Inc Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine
TW202305009A (zh) 2021-04-08 2023-02-01 美商默沙東有限責任公司 以皮下投予抗pd1抗體治療癌症之方法
EP4424301A4 (en) 2021-10-29 2025-11-19 Alteogen Inc Pharmaceutical composition comprising a human PH20 hyaluronidase and a medicinal product
KR20250054235A (ko) 2022-07-28 2025-04-22 머크 샤프 앤드 돔 엘엘씨 프로그램화된 사멸 수용체 1 (PD-1) 항체 및 rHuPH20 또는 그의 변이체 또는 단편의 제약 조성물
EP4562048A1 (en) 2022-07-28 2025-06-04 Merck Sharp & Dohme LLC Pharmaceutical compositions of programmed death receptor 1 (pd-1) antibodies and ph20 variants or fragments thereof
AU2023361392A1 (en) 2022-10-12 2025-05-29 Merck Sharp & Dohme Llc Compositions and methods for treating cancer with subcutaneous administration of anti-pd1 antibodies
WO2024081274A1 (en) 2022-10-12 2024-04-18 Merck Sharp & Dohme Llc Compositions and methods for treating cancer with subcutaneous administration of anti-pd1 antibodies

Also Published As

Publication number Publication date
PE20220283A1 (es) 2022-02-25
AU2020248612A1 (en) 2021-10-21
EP4461811A2 (en) 2024-11-13
JP2025102750A (ja) 2025-07-08
SG11202110512WA (en) 2021-10-28
WO2020197230A1 (ko) 2020-10-01
JP2021526542A (ja) 2021-10-07
JP2023078146A (ja) 2023-06-06
CA3131052A1 (en) 2020-10-01
CN120053667A (zh) 2025-05-30
ECSP21070640A (es) 2021-11-18
BR112021019076A2 (pt) 2021-11-30
AU2024201238A1 (en) 2024-03-14
ZA202108027B (en) 2022-12-21
MY204342A (en) 2024-08-24
KR102650991B9 (ko) 2026-03-19
PH12021552351A1 (en) 2022-09-12
EP4461811A3 (en) 2025-01-08
EA202192588A1 (ru) 2022-03-17
DOP2021000197A (es) 2021-11-15
KR20200130451A (ko) 2020-11-18
MX2021011278A (es) 2022-03-17
AU2020248612B2 (en) 2023-11-23
CN116870164A (zh) 2023-10-13
EP3785701A1 (en) 2021-03-03
SA521430398B1 (ar) 2024-05-14
JP2022095925A (ja) 2022-06-28
AU2024201238B2 (en) 2026-02-12
IL286539A (en) 2021-10-31
CN120053665A (zh) 2025-05-30
EP3785701A4 (en) 2022-03-16
NI202100085A (es) 2021-12-06
US12570766B2 (en) 2026-03-10
US20210363270A1 (en) 2021-11-25
JOP20210262A1 (ar) 2023-01-30
KR102650991B1 (ko) 2024-03-27
AU2020248612B9 (en) 2023-11-30
CO2021012380A2 (es) 2021-10-20
CN112203642B (zh) 2025-03-07
CN117100867A (zh) 2023-11-24
CN112203642A (zh) 2021-01-08
CN116870164B (zh) 2024-07-23
JP7295150B2 (ja) 2023-06-20
US20220289864A1 (en) 2022-09-15
CN120053666A (zh) 2025-05-30
ZA202209369B (en) 2023-07-26
JP7166478B2 (ja) 2022-11-07
KR102507853B9 (ko) 2026-03-13
KR20220075238A (ko) 2022-06-07
CR20210489A (es) 2021-12-07
KR102507853B1 (ko) 2023-03-10
KR20230037691A (ko) 2023-03-16
MX2024009997A (es) 2024-12-06
CN121015892A (zh) 2025-11-28

Similar Documents

Publication Publication Date Title
CL2021002464A1 (es) Composición farmacéutica, que comprende la variante de hialuronidasa humana ph20 y fármaco, para inyección subcutánea.
MX2024005173A (es) Composicion farmaceutica que comprende hialuronidasa humana ph20 y farmaco.
AU2019311658A8 (en) Novel hyaluronidase variants and pharmaceutical composition comprising the same
PE20191203A1 (es) Variantes de alfa-glucosidasa acida y usos de las mismas
AR108442A1 (es) Proteínas de fusión gdf15 y usos de estas
CO6190536A2 (es) Vacunas peptidicas para canceres que expresan antigenos asociados con tumores
MX2009004147A (es) Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1.
MX2024015050A (es) L-asparaginasa modificada
AR064555A1 (es) Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo
PE20081140A1 (es) Agentes terapeuticos a base de peptidos derivados de toxinas
PE20090932A1 (es) Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1
NO345236B1 (no) Glukagonlignende peptid-2 (GLP-2) analoger, farmasøytiske sammensetninger inneholdende slike og anvendelse for fremstillingen av et medikament for behandlingen og/eller forebyggingen av en mage- og tarmrelatert lidelse, samt nukleinsyremolekyl, ekspresjonsvektor, vertscelle og fremgangsmåter for fremstilling av GLP-2 analogene og et terapeutisk sett.
PE20120792A1 (es) Variantes de peptidos natriureticos de tipo c
PE20090682A1 (es) Secuencias peptidicas y composiciones
RU2017119773A (ru) Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение
AR024335A1 (es) Hialuronidasa de hirudinaria manillensis, aislamiento, purificacion y metodo recombinante de produccion
CO6260151A2 (es) Peptido de cdh3 y agente medicinal que comprende al mismo
PE20201254A1 (es) Analogos de compstatina y sus usos medicos
NZ614557A (en) Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
BR0318594A (pt) proteìna recombinante que possui um efeito anticancerìgeno, seu gene de codificação e usos desta
ATE552271T1 (de) Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon
AU2016232361B2 (en) Cyclic galanin-analogs and uses thereof
AR114927A1 (es) Neoantígenos y usos de los mismos
EA202092017A1 (ru) Новые аналоги glp-1
DE602007009797D1 (de) Antitumorheilmittel, Medikament, Zusammensetzung und Verwendung davon